Oxagen Raises £16 Million
Oxagen Ltd., a UK-based drug company focused on inflammation, has raised £16 million in Series C funding. Novartis Venture Funds led the round, and was joined by return backers MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega, Abingworth, IBT, Red Abbey and The Wellcome Trust.
24 November 2009•2 mins read
